Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
VANCOUVER, British Columbia, Jan. 28, 2016 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming LEERINK Partners 5th Annual Global Healthcare Conference in New York city on Thursday, February 11th 2016 at 1:50 PM Eastern Time.
A live audio webcast and archive of the event will be available at: http://wsw.com/webcast/leerink26/aqxp
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing slated to enter Phase 3 clinical trials in 2016 for the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC); a debilitating, chronic condition that is estimated to affect millions of sufferers. Aquinox has a broad intellectual property portfolio surrounding compounds that activate SHIP1. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.629.9223 Ext. 109
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
